ICPT News and Press, Intercept Pharmaceuticals Inc. From 05/19/23

MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that NASDAQ has halted trading of th...

2023-05-17 15:46:08 ET Intercept Pharma ( NASDAQ: ICPT ) continued to drop Wednesday after the FDA issued briefing documents ahead of an AdCom meeting on its marketing application for lead asset Obeticholic Acid (OCA) in liver disease NASH while Raymond James downgraded the stock ci...

2023-05-17 15:31:52 ET Intercept Pharma ( NASDAQ: ICPT ) continued to drop Wednesday after the FDA issued briefing documents ahead of an AdCom meeting on its marketing application for lead asset Obeticholic Acid (OCA) in liver disease NASH while Jefferies downgraded the stock citing...

2023-05-17 12:56:05 ET Gainers: Immutep Limited ( IMMP ) +114% . WeTrade Group ( WETG ) +56% . Smart for Life ( SMFL ) +56% . National Western Life Group ( NWLI ) +40% . Bausch Health Companies ( BHC ) +37% . SelectQuote ( ...

2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...

2023-05-17 09:51:01 ET Intercept Pharmaceuticals ( NASDAQ: ICPT ) lost ~26% in the morning hours Wednesday after the FDA issued briefing documents ahead of a meeting of its independent advisors on the marketing application for the company's liver disease candidate Obeticholic Ac...

Company on track to complete planned interim analyses from two ongoing Phase 2 studies of the OCA-bezafibrate combination in 2023 Results from planned interim analysis of Phase 2 study evaluating the effects of OCA and bezafibrate on serum biomarkers in PBC to be presented at EASL Congr...

2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

2023-04-27 15:49:00 ET Shares of the non-viral liver disease specialist Intercept Pharmaceuticals (NASDAQ: ICPT) are under heavy pressure today. Specifically, the drugmaker's stock was down by 9.7% on exceptionally high volume as of 3:02 p.m. ET Thursday afternoon. The big loss ...